Application of blood biomarkers for the future anti‐Aβ antibody therapy in Japan Article Swipe
Kensaku Kasuga
,
Tamao Tsukie
,
Kazuya Igarashi
,
Takanobu Ishiguro
,
Akinori Miyashita
,
Osamu Onodera
,
Takeshi Ikeuchi
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1002/alz.084859
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1002/alz.084859
Background With the approval of Lecanemab in Japan following the U.S., biomarker‐based diagnosis of AD will be required in daily practice. However, PET or CSF are limited by cost, low availability, and invasiveness. In addition, frequent MRI is required to monitor amyloid‐related imaging abnormalities (ARIA), an adverse event unique to anti‐Aβ antibodies. Blood biomarkers are expected to be inexpensive, less invasive, and acceptable for frequent testing in daily practice. Method Of the cases analyzed for AD‐related CSF biomarkers for diagnostic purposes from Department of Neurology, Niigata University and related facilities, 217 plasma available cases were included. Of the 217 cases, 113 were clinically diagnosed as Alzheimer's clinical syndrome (ACS) and 104 as non‐ACS, including 6 cerebral amyloid angiopathy related inflammation (CAAri) cases. CSF Aβ42/40 ratio, phosphorylated tau (pTau181), neurofilament light chain (NfL), and plasma pTau181 and NfL were measured. According to the research framework, AD was determined when both CSF Aβ42/40 ratio (as A marker) and CSF pTau181 (as T marker) were positive. The ROC curve was used to verify the accuracy of plasma pTau181 in differentiating AD from non‐AD, and the accuracy of plasma NfL in differentiating AD from CAAri, which has been suggested to share a common pathology with ARIA. Result Plasma pTau181 differentiated AD group (CSF A+T+) from non‐AD group with high accuracy (AUC = 0.867). Plasma pTau181 also differentiated A+ group from A‐ group with high accuracy (AUC = 0.913, sensitivity 89.7%, specificity 82.9%). When the low‐risk threshold was made more stringent (Sensitivity 90%, 95%, 100%), negative predict value increased (78.1%, 88.9%, 100%). When the high‐risk threshold was made more stringent (Specificity 90%, 95%, 100%), positive predictive value increased (78.1%, 88.9%, 100%). However, as a trade‐off, the number of the intermediate risk group increased (16%, 35%, 81%). Plasma NfL discriminated CAAri group from AD group (ACS and CSF A+T+) with high accuracy (AUC = 0.947). Conclusion In Japanese clinical practice, plasma pTau181 is considered to be useful for detecting AD pathology, and is expected to be utilized for screening of anti‐Aβ antibody therapy. Plasma NfL may also be useful in screening for adverse events of anti‐Aβ antibodies.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1002/alz.084859
- OA Status
- hybrid
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4406209820
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4406209820Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1002/alz.084859Digital Object Identifier
- Title
-
Application of blood biomarkers for the future anti‐Aβ antibody therapy in JapanWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-12-01Full publication date if available
- Authors
-
Kensaku Kasuga, Tamao Tsukie, Kazuya Igarashi, Takanobu Ishiguro, Akinori Miyashita, Osamu Onodera, Takeshi IkeuchiList of authors in order
- Landing page
-
https://doi.org/10.1002/alz.084859Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1002/alz.084859Direct OA link when available
- Concepts
-
Antibody, Medicine, Antibody therapy, Intensive care medicine, Immunology, Monoclonal antibodyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4406209820 |
|---|---|
| doi | https://doi.org/10.1002/alz.084859 |
| ids.doi | https://doi.org/10.1002/alz.084859 |
| ids.openalex | https://openalex.org/W4406209820 |
| fwci | 0.0 |
| type | article |
| title | Application of blood biomarkers for the future anti‐Aβ antibody therapy in Japan |
| biblio.issue | S2 |
| biblio.volume | 20 |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T11016 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9991999864578247 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2741 |
| topics[0].subfield.display_name | Radiology, Nuclear Medicine and Imaging |
| topics[0].display_name | Monoclonal and Polyclonal Antibodies Research |
| topics[1].id | https://openalex.org/T10602 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9976999759674072 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1312 |
| topics[1].subfield.display_name | Molecular Biology |
| topics[1].display_name | Glycosylation and Glycoproteins Research |
| topics[2].id | https://openalex.org/T11157 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9918000102043152 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2716 |
| topics[2].subfield.display_name | Genetics |
| topics[2].display_name | Chronic Lymphocytic Leukemia Research |
| is_xpac | False |
| apc_list.value | 4000 |
| apc_list.currency | USD |
| apc_list.value_usd | 4000 |
| apc_paid.value | 4000 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 4000 |
| concepts[0].id | https://openalex.org/C159654299 |
| concepts[0].level | 2 |
| concepts[0].score | 0.6012597680091858 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[0].display_name | Antibody |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.5938418507575989 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C2908856526 |
| concepts[2].level | 4 |
| concepts[2].score | 0.4938841462135315 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q16252627 |
| concepts[2].display_name | Antibody therapy |
| concepts[3].id | https://openalex.org/C177713679 |
| concepts[3].level | 1 |
| concepts[3].score | 0.3311258852481842 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q679690 |
| concepts[3].display_name | Intensive care medicine |
| concepts[4].id | https://openalex.org/C203014093 |
| concepts[4].level | 1 |
| concepts[4].score | 0.32115262746810913 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[4].display_name | Immunology |
| concepts[5].id | https://openalex.org/C542903549 |
| concepts[5].level | 3 |
| concepts[5].score | 0.13249316811561584 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q422248 |
| concepts[5].display_name | Monoclonal antibody |
| keywords[0].id | https://openalex.org/keywords/antibody |
| keywords[0].score | 0.6012597680091858 |
| keywords[0].display_name | Antibody |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.5938418507575989 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/antibody-therapy |
| keywords[2].score | 0.4938841462135315 |
| keywords[2].display_name | Antibody therapy |
| keywords[3].id | https://openalex.org/keywords/intensive-care-medicine |
| keywords[3].score | 0.3311258852481842 |
| keywords[3].display_name | Intensive care medicine |
| keywords[4].id | https://openalex.org/keywords/immunology |
| keywords[4].score | 0.32115262746810913 |
| keywords[4].display_name | Immunology |
| keywords[5].id | https://openalex.org/keywords/monoclonal-antibody |
| keywords[5].score | 0.13249316811561584 |
| keywords[5].display_name | Monoclonal antibody |
| language | en |
| locations[0].id | doi:10.1002/alz.084859 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S108427512 |
| locations[0].source.issn | 1552-5260, 1552-5279 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1552-5260 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Alzheimer s & Dementia |
| locations[0].source.host_organization | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_name | Wiley |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320595 |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Alzheimer's & Dementia |
| locations[0].landing_page_url | https://doi.org/10.1002/alz.084859 |
| locations[1].id | pmh:oai:pubmedcentral.nih.gov:11714849 |
| locations[1].is_oa | True |
| locations[1].source.id | https://openalex.org/S2764455111 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed Central |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | other-oa |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | Text |
| locations[1].license_id | https://openalex.org/licenses/other-oa |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | Alzheimers Dement |
| locations[1].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11714849 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5042702577 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-2178-0769 |
| authorships[0].author.display_name | Kensaku Kasuga |
| authorships[0].countries | JP |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I71395657 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Niigata Japan |
| authorships[0].institutions[0].id | https://openalex.org/I71395657 |
| authorships[0].institutions[0].ror | https://ror.org/04ww21r56 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I71395657 |
| authorships[0].institutions[0].country_code | JP |
| authorships[0].institutions[0].display_name | Niigata University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Kensaku Kasuga |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Niigata Japan |
| authorships[1].author.id | https://openalex.org/A5025142797 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Tamao Tsukie |
| authorships[1].countries | JP |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I71395657 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Niigata Japan |
| authorships[1].institutions[0].id | https://openalex.org/I71395657 |
| authorships[1].institutions[0].ror | https://ror.org/04ww21r56 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I71395657 |
| authorships[1].institutions[0].country_code | JP |
| authorships[1].institutions[0].display_name | Niigata University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Tamao Tsukie |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Niigata Japan |
| authorships[2].author.id | https://openalex.org/A5023231487 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Kazuya Igarashi |
| authorships[2].countries | JP |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I71395657 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata Japan |
| authorships[2].institutions[0].id | https://openalex.org/I71395657 |
| authorships[2].institutions[0].ror | https://ror.org/04ww21r56 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I71395657 |
| authorships[2].institutions[0].country_code | JP |
| authorships[2].institutions[0].display_name | Niigata University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Kazuya Igarashi |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata Japan |
| authorships[3].author.id | https://openalex.org/A5039282643 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-8205-4912 |
| authorships[3].author.display_name | Takanobu Ishiguro |
| authorships[3].countries | JP |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I71395657 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Neurology, Brain Research Institute, Niigata University, Niigata Japan |
| authorships[3].institutions[0].id | https://openalex.org/I71395657 |
| authorships[3].institutions[0].ror | https://ror.org/04ww21r56 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I71395657 |
| authorships[3].institutions[0].country_code | JP |
| authorships[3].institutions[0].display_name | Niigata University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Takanobu Ishiguro |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Neurology, Brain Research Institute, Niigata University, Niigata Japan |
| authorships[4].author.id | https://openalex.org/A5090432651 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-2508-9649 |
| authorships[4].author.display_name | Akinori Miyashita |
| authorships[4].countries | JP |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I71395657 |
| authorships[4].affiliations[0].raw_affiliation_string | Brain Research Institute, Niigata University, Niigata, Niigata Japan |
| authorships[4].institutions[0].id | https://openalex.org/I71395657 |
| authorships[4].institutions[0].ror | https://ror.org/04ww21r56 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I71395657 |
| authorships[4].institutions[0].country_code | JP |
| authorships[4].institutions[0].display_name | Niigata University |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Akinori Miyashita |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Brain Research Institute, Niigata University, Niigata, Niigata Japan |
| authorships[5].author.id | https://openalex.org/A5088062381 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-3354-5472 |
| authorships[5].author.display_name | Osamu Onodera |
| authorships[5].countries | JP |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I71395657 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Neurology, Brain Research Institute, Niigata University, Niigata Japan |
| authorships[5].institutions[0].id | https://openalex.org/I71395657 |
| authorships[5].institutions[0].ror | https://ror.org/04ww21r56 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I71395657 |
| authorships[5].institutions[0].country_code | JP |
| authorships[5].institutions[0].display_name | Niigata University |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Osamu Onodera |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Neurology, Brain Research Institute, Niigata University, Niigata Japan |
| authorships[6].author.id | https://openalex.org/A5023346646 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-8828-8085 |
| authorships[6].author.display_name | Takeshi Ikeuchi |
| authorships[6].countries | JP |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I71395657 |
| authorships[6].affiliations[0].raw_affiliation_string | Brain Research Institute, Niigata University, Niigata, Niigata Japan |
| authorships[6].institutions[0].id | https://openalex.org/I71395657 |
| authorships[6].institutions[0].ror | https://ror.org/04ww21r56 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I71395657 |
| authorships[6].institutions[0].country_code | JP |
| authorships[6].institutions[0].display_name | Niigata University |
| authorships[6].author_position | last |
| authorships[6].raw_author_name | Takeshi Ikeuchi |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Brain Research Institute, Niigata University, Niigata, Niigata Japan |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1002/alz.084859 |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Application of blood biomarkers for the future anti‐Aβ antibody therapy in Japan |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11016 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9991999864578247 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2741 |
| primary_topic.subfield.display_name | Radiology, Nuclear Medicine and Imaging |
| primary_topic.display_name | Monoclonal and Polyclonal Antibodies Research |
| related_works | https://openalex.org/W2899084033, https://openalex.org/W2748952813, https://openalex.org/W3031052312, https://openalex.org/W4389568370, https://openalex.org/W3032375762, https://openalex.org/W1995515455, https://openalex.org/W2080531066, https://openalex.org/W3108674512, https://openalex.org/W1506200166, https://openalex.org/W2021084977 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1002/alz.084859 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S108427512 |
| best_oa_location.source.issn | 1552-5260, 1552-5279 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 1552-5260 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Alzheimer s & Dementia |
| best_oa_location.source.host_organization | https://openalex.org/P4310320595 |
| best_oa_location.source.host_organization_name | Wiley |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Alzheimer's & Dementia |
| best_oa_location.landing_page_url | https://doi.org/10.1002/alz.084859 |
| primary_location.id | doi:10.1002/alz.084859 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S108427512 |
| primary_location.source.issn | 1552-5260, 1552-5279 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1552-5260 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Alzheimer s & Dementia |
| primary_location.source.host_organization | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_name | Wiley |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Alzheimer's & Dementia |
| primary_location.landing_page_url | https://doi.org/10.1002/alz.084859 |
| publication_date | 2024-12-01 |
| publication_year | 2024 |
| referenced_works_count | 0 |
| abstract_inverted_index.6 | 115 |
| abstract_inverted_index.= | 218, 233, 308 |
| abstract_inverted_index.A | 154 |
| abstract_inverted_index.T | 160 |
| abstract_inverted_index.a | 198, 279 |
| abstract_inverted_index.A+ | 224 |
| abstract_inverted_index.AD | 15, 145, 178, 189, 207, 298, 324 |
| abstract_inverted_index.In | 34, 311 |
| abstract_inverted_index.Of | 71, 97 |
| abstract_inverted_index.an | 46 |
| abstract_inverted_index.as | 105, 112, 278 |
| abstract_inverted_index.be | 17, 58, 320, 330, 342 |
| abstract_inverted_index.by | 28 |
| abstract_inverted_index.in | 7, 19, 67, 176, 187, 344 |
| abstract_inverted_index.is | 38, 317, 327 |
| abstract_inverted_index.of | 5, 14, 84, 173, 184, 283, 334, 349 |
| abstract_inverted_index.or | 24 |
| abstract_inverted_index.to | 40, 50, 57, 141, 169, 196, 319, 329 |
| abstract_inverted_index.(as | 153, 159 |
| abstract_inverted_index.104 | 111 |
| abstract_inverted_index.113 | 101 |
| abstract_inverted_index.217 | 91, 99 |
| abstract_inverted_index.CSF | 25, 77, 123, 150, 157, 302 |
| abstract_inverted_index.MRI | 37 |
| abstract_inverted_index.NfL | 137, 186, 293, 339 |
| abstract_inverted_index.PET | 23 |
| abstract_inverted_index.ROC | 165 |
| abstract_inverted_index.The | 164 |
| abstract_inverted_index.and | 32, 62, 88, 110, 133, 136, 156, 181, 301, 326 |
| abstract_inverted_index.are | 26, 55 |
| abstract_inverted_index.for | 64, 75, 79, 322, 332, 346 |
| abstract_inverted_index.has | 193 |
| abstract_inverted_index.low | 30 |
| abstract_inverted_index.may | 340 |
| abstract_inverted_index.tau | 127 |
| abstract_inverted_index.the | 3, 10, 72, 98, 142, 171, 182, 240, 259, 281, 284 |
| abstract_inverted_index.was | 146, 167, 243, 262 |
| abstract_inverted_index.(ACS | 300 |
| abstract_inverted_index.(AUC | 217, 232, 307 |
| abstract_inverted_index.(CSF | 209 |
| abstract_inverted_index.35%, | 290 |
| abstract_inverted_index.90%, | 248, 267 |
| abstract_inverted_index.95%, | 249, 268 |
| abstract_inverted_index.A‐ | 227 |
| abstract_inverted_index.When | 239, 258 |
| abstract_inverted_index.With | 2 |
| abstract_inverted_index.also | 222, 341 |
| abstract_inverted_index.been | 194 |
| abstract_inverted_index.both | 149 |
| abstract_inverted_index.from | 82, 179, 190, 211, 226, 297 |
| abstract_inverted_index.high | 215, 230, 305 |
| abstract_inverted_index.less | 60 |
| abstract_inverted_index.made | 244, 263 |
| abstract_inverted_index.more | 245, 264 |
| abstract_inverted_index.risk | 286 |
| abstract_inverted_index.used | 168 |
| abstract_inverted_index.were | 95, 102, 138, 162 |
| abstract_inverted_index.when | 148 |
| abstract_inverted_index.will | 16 |
| abstract_inverted_index.with | 201, 214, 229, 304 |
| abstract_inverted_index.(16%, | 289 |
| abstract_inverted_index.(ACS) | 109 |
| abstract_inverted_index.81%). | 291 |
| abstract_inverted_index.A+T+) | 210, 303 |
| abstract_inverted_index.ARIA. | 202 |
| abstract_inverted_index.Blood | 53 |
| abstract_inverted_index.CAAri | 295 |
| abstract_inverted_index.Japan | 8 |
| abstract_inverted_index.U.S., | 11 |
| abstract_inverted_index.cases | 73, 94 |
| abstract_inverted_index.chain | 131 |
| abstract_inverted_index.cost, | 29 |
| abstract_inverted_index.curve | 166 |
| abstract_inverted_index.daily | 20, 68 |
| abstract_inverted_index.event | 48 |
| abstract_inverted_index.group | 208, 213, 225, 228, 287, 296, 299 |
| abstract_inverted_index.light | 130 |
| abstract_inverted_index.ratio | 152 |
| abstract_inverted_index.share | 197 |
| abstract_inverted_index.value | 253, 272 |
| abstract_inverted_index.which | 192 |
| abstract_inverted_index.(NfL), | 132 |
| abstract_inverted_index.0.913, | 234 |
| abstract_inverted_index.100%), | 250, 269 |
| abstract_inverted_index.100%). | 257, 276 |
| abstract_inverted_index.88.9%, | 256, 275 |
| abstract_inverted_index.89.7%, | 236 |
| abstract_inverted_index.CAAri, | 191 |
| abstract_inverted_index.Method | 70 |
| abstract_inverted_index.Plasma | 204, 220, 292, 338 |
| abstract_inverted_index.Result | 203 |
| abstract_inverted_index.cases, | 100 |
| abstract_inverted_index.cases. | 122 |
| abstract_inverted_index.common | 199 |
| abstract_inverted_index.events | 348 |
| abstract_inverted_index.number | 282 |
| abstract_inverted_index.plasma | 92, 134, 174, 185, 315 |
| abstract_inverted_index.ratio, | 125 |
| abstract_inverted_index.unique | 49 |
| abstract_inverted_index.useful | 321, 343 |
| abstract_inverted_index.verify | 170 |
| abstract_inverted_index.(78.1%, | 255, 274 |
| abstract_inverted_index.(ARIA), | 45 |
| abstract_inverted_index.(CAAri) | 121 |
| abstract_inverted_index.0.867). | 219 |
| abstract_inverted_index.0.947). | 309 |
| abstract_inverted_index.82.9%). | 238 |
| abstract_inverted_index.Niigata | 86 |
| abstract_inverted_index.adverse | 47, 347 |
| abstract_inverted_index.amyloid | 117 |
| abstract_inverted_index.imaging | 43 |
| abstract_inverted_index.limited | 27 |
| abstract_inverted_index.marker) | 155, 161 |
| abstract_inverted_index.monitor | 41 |
| abstract_inverted_index.pTau181 | 135, 158, 175, 205, 221, 316 |
| abstract_inverted_index.predict | 252 |
| abstract_inverted_index.related | 89, 119 |
| abstract_inverted_index.testing | 66 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Aβ42/40 | 124, 151 |
| abstract_inverted_index.However, | 22, 277 |
| abstract_inverted_index.Japanese | 312 |
| abstract_inverted_index.accuracy | 172, 183, 216, 231, 306 |
| abstract_inverted_index.analyzed | 74 |
| abstract_inverted_index.antibody | 336 |
| abstract_inverted_index.approval | 4 |
| abstract_inverted_index.cerebral | 116 |
| abstract_inverted_index.clinical | 107, 313 |
| abstract_inverted_index.expected | 56, 328 |
| abstract_inverted_index.frequent | 36, 65 |
| abstract_inverted_index.negative | 251 |
| abstract_inverted_index.non‐AD | 212 |
| abstract_inverted_index.positive | 270 |
| abstract_inverted_index.purposes | 81 |
| abstract_inverted_index.required | 18, 39 |
| abstract_inverted_index.research | 143 |
| abstract_inverted_index.syndrome | 108 |
| abstract_inverted_index.therapy. | 337 |
| abstract_inverted_index.utilized | 331 |
| abstract_inverted_index.According | 140 |
| abstract_inverted_index.Lecanemab | 6 |
| abstract_inverted_index.addition, | 35 |
| abstract_inverted_index.available | 93 |
| abstract_inverted_index.detecting | 323 |
| abstract_inverted_index.diagnosed | 104 |
| abstract_inverted_index.diagnosis | 13 |
| abstract_inverted_index.following | 9 |
| abstract_inverted_index.included. | 96 |
| abstract_inverted_index.including | 114 |
| abstract_inverted_index.increased | 254, 273, 288 |
| abstract_inverted_index.invasive, | 61 |
| abstract_inverted_index.measured. | 139 |
| abstract_inverted_index.non‐AD, | 180 |
| abstract_inverted_index.pathology | 200 |
| abstract_inverted_index.positive. | 163 |
| abstract_inverted_index.practice, | 314 |
| abstract_inverted_index.practice. | 21, 69 |
| abstract_inverted_index.screening | 333, 345 |
| abstract_inverted_index.stringent | 246, 265 |
| abstract_inverted_index.suggested | 195 |
| abstract_inverted_index.threshold | 242, 261 |
| abstract_inverted_index.(pTau181), | 128 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Conclusion | 310 |
| abstract_inverted_index.Department | 83 |
| abstract_inverted_index.Neurology, | 85 |
| abstract_inverted_index.University | 87 |
| abstract_inverted_index.acceptable | 63 |
| abstract_inverted_index.angiopathy | 118 |
| abstract_inverted_index.anti‐Aβ | 51, 335, 350 |
| abstract_inverted_index.biomarkers | 54, 78 |
| abstract_inverted_index.clinically | 103 |
| abstract_inverted_index.considered | 318 |
| abstract_inverted_index.determined | 147 |
| abstract_inverted_index.diagnostic | 80 |
| abstract_inverted_index.framework, | 144 |
| abstract_inverted_index.low‐risk | 241 |
| abstract_inverted_index.non‐ACS, | 113 |
| abstract_inverted_index.pathology, | 325 |
| abstract_inverted_index.predictive | 271 |
| abstract_inverted_index.Alzheimer's | 106 |
| abstract_inverted_index.antibodies. | 52, 351 |
| abstract_inverted_index.facilities, | 90 |
| abstract_inverted_index.high‐risk | 260 |
| abstract_inverted_index.sensitivity | 235 |
| abstract_inverted_index.specificity | 237 |
| abstract_inverted_index.(Sensitivity | 247 |
| abstract_inverted_index.(Specificity | 266 |
| abstract_inverted_index.AD‐related | 76 |
| abstract_inverted_index.inexpensive, | 59 |
| abstract_inverted_index.inflammation | 120 |
| abstract_inverted_index.intermediate | 285 |
| abstract_inverted_index.trade‐off, | 280 |
| abstract_inverted_index.abnormalities | 44 |
| abstract_inverted_index.availability, | 31 |
| abstract_inverted_index.discriminated | 294 |
| abstract_inverted_index.invasiveness. | 33 |
| abstract_inverted_index.neurofilament | 129 |
| abstract_inverted_index.differentiated | 206, 223 |
| abstract_inverted_index.phosphorylated | 126 |
| abstract_inverted_index.differentiating | 177, 188 |
| abstract_inverted_index.amyloid‐related | 42 |
| abstract_inverted_index.biomarker‐based | 12 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 7 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.5600000023841858 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.46888924 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |